MSLN and neoplasm: In contrast, Meso-CAR T cells had no impact on FAP+ cells at any time-point compared to MigR control T cells and only modestly reduced the proportion of Mesothelin+ tumor cells and with more delayed kinetics, being evident only at day 7 compared to the more rapid impact of FAP-CAR T cells on the proportion of FAP+ stromal cells at all time-points (Fig. 2f).